|
|
Line 3: |
Line 3: |
| <StructureSection load='6tx1' size='340' side='right'caption='[[6tx1]], [[Resolution|resolution]] 2.09Å' scene=''> | | <StructureSection load='6tx1' size='340' side='right'caption='[[6tx1]], [[Resolution|resolution]] 2.09Å' scene=''> |
| == Structural highlights == | | == Structural highlights == |
- | <table><tr><td colspan='2'>[[6tx1]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Nemve Nemve]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TX1 OCA]. For a <b>guided tour on the structure components</b> use [http://proteopedia.org/fgij/fg.htm?mol=6TX1 FirstGlance]. <br> | + | <table><tr><td colspan='2'>[[6tx1]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Nematostella_vectensis Nematostella vectensis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6TX1 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6TX1 FirstGlance]. <br> |
- | </td></tr><tr id='gene'><td class="sblockLbl"><b>[[Gene|Gene:]]</b></td><td class="sblockDat">v1g201271 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=45351 NEMVE])</td></tr> | + | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.091Å</td></tr> |
- | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://proteopedia.org/fgij/fg.htm?mol=6tx1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tx1 OCA], [http://pdbe.org/6tx1 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=6tx1 RCSB], [http://www.ebi.ac.uk/pdbsum/6tx1 PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=6tx1 ProSAT]</span></td></tr> | + | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6tx1 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6tx1 OCA], [https://pdbe.org/6tx1 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6tx1 RCSB], [https://www.ebi.ac.uk/pdbsum/6tx1 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6tx1 ProSAT]</span></td></tr> |
| </table> | | </table> |
- | <div style="background-color:#fffaf0;">
| + | == Function == |
- | == Publication Abstract from PubMed == | + | [https://www.uniprot.org/uniprot/HPF1_NEMVE HPF1_NEMVE] Cofactor for serine ADP-ribosylation that confers serine specificity on PARP. Switches the amino acid specificity of PARP from aspartate or glutamate to serine residues. Acts by completing the active site of PARP: forms a composite active site composed of residues from HPF1 and PARP.[UniProtKB:Q9NWY4] |
- | The anti-cancer drug target poly(ADP-ribose) polymerase 1 (PARP1) and its close homologue, PARP2, are early responders to DNA damage in human cells(1,2). Upon binding to genomic lesions, these enzymes utilise NAD(+) to modify a plethora of proteins with mono- and poly(ADP-ribose) signals that are important for subsequent chromatin decompaction and repair factor recruitment(3,4). These post-translational modification events are predominantly serine-linked and require HPF1, an accessory factor that is specific for the DNA damage response and switches the amino-acid specificity of PARP1/2 from aspartate/glutamate to serine residues(5-10). Here, we report a co-structure of HPF1 bound to the catalytic domain of PARP2 that, in combination with NMR and biochemical data, reveals a composite active site formed by residues from both PARP1/2 and HPF1. We further show that the assembly of this new catalytic centre is essential for DNA damage-induced protein ADP-ribosylation in human cells. In response to DNA damage and NAD(+) binding site occupancy, the HPF1-PARP1/2 interaction is enhanced via allosteric networks operating within PARP1/2, providing an additional level of regulation in DNA repair induction. As HPF1 forms a joint active site with PARP1/2, our data implicate HPF1 as an important determinant of the response to clinical PARP inhibitors.
| + | |
- | | + | |
- | HPF1 completes the PARP active site for DNA damage-induced ADP-ribosylation.,Suskiewicz MJ, Zobel F, Ogden TEH, Fontana P, Ariza A, Yang JC, Zhu K, Bracken L, Hawthorne WJ, Ahel D, Neuhaus D, Ahel I Nature. 2020 Feb 6. pii: 10.1038/s41586-020-2013-6. doi:, 10.1038/s41586-020-2013-6. PMID:32028527<ref>PMID:32028527</ref>
| + | |
- | | + | |
- | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
| + | |
- | </div>
| + | |
- | <div class="pdbe-citations 6tx1" style="background-color:#fffaf0;"></div>
| + | |
- | == References ==
| + | |
- | <references/>
| + | |
| __TOC__ | | __TOC__ |
| </StructureSection> | | </StructureSection> |
| [[Category: Large Structures]] | | [[Category: Large Structures]] |
- | [[Category: Nemve]] | + | [[Category: Nematostella vectensis]] |
- | [[Category: Ahel, I]] | + | [[Category: Ahel I]] |
- | [[Category: Suskiewicz, M J]] | + | [[Category: Suskiewicz MJ]] |
- | [[Category: Adaptor]]
| + | |
- | [[Category: Adp-ribosylation]]
| + | |
- | [[Category: Parp1]]
| + | |
- | [[Category: Parp2]]
| + | |
- | [[Category: Protein binding]]
| + | |
- | [[Category: Serine adp-ribosylation]]
| + | |